Mylan settles with Warner Chilcott over generic version of Femcon Fe

Mylan can launch generic upon FDA approval

PITTSBURGH — Generic drug maker Mylan has settled with Warner Chilcott in a case concerning an oral contraceptive.

Mylan said Wednesday that it and Famy Care had entered into an agreement with Warner Chilcott resolving a lawsuit over Femcon Fe (norethindrone and ethinyl estradiol chewable tablets, ferrous fumarate tablets).

Under the settlement, the litigation has been dismissed, and Mylan can begin marketing and selling a generic version of the drug once it receives approval from the Food and Drug Administration. Additional details of the settlement are confidential, Mylan said.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Login or Register to post a comment.